Completed OBSERVATIONAL NCT03479099

Liquid Biopsy in Lung Cancer

Clinical Utility of Combined CTC and ctDNA Assay in the Diagnosis of Primary Lung Cancer

Sponsor: Samsung Medical Center

Conditions Circulating Tumor Cell Lung Cancer (Diagnosis)

Updated 7 times since 2018 Last updated: Aug 24, 2019 Started: Mar 12, 2018 Primary completion: Mar 11, 2019 Completion: Mar 11, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03479099, this observational or N/A phase trial focuses on Circulating Tumor Cell and Lung Cancer (Diagnosis) and remains completed. Sponsored by Samsung Medical Center, it has been updated 7 times since 2018, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed
Sep 2024 — Sep 2025 [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Sep 2019 — Jan 2021 [monthly]

Completed

Status: Recruiting → Completed

▶ Show 2 earlier versions

Jun 2018 — Sep 2019 [monthly]

Recruiting
Apr 2018 — Jun 2018 [monthly]

Recruiting

First recorded

Mar 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Samsung Medical Center

Data source: Samsung Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea